510(k) Report

510(k) · Cleared

Recalled · 2000

The Aptus (Automated) Application of the Rubella Igm Elisa Test System

K984180510(k) TraditionalCleared Jul 20, 1999239-day reviewClass II21 CFR 866.3510Recalls 1

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Zeus Scientific, Inc. · LFX Enzyme Linked Immunoabsorbent Assay, Rubella

Cleared on Jul 20, 1999 after a 239-day review. FDA’s file for it is a 510(k) statement, which names no predicate. 6 later devices descend from it. It has been recalled once.

Decided
Jul 20, 1999
Review
239 days
Class
Class II
Product code
LFX
Recalls
1
Predicates
0

6 later devices descend from it, 2 citing it directly.

Descendants, by year cleared 2008: 1 descendant cleared2010: 1 descendant cleared2014: 2 descendants cleared2022: 1 descendant cleared2017: 1 descendant cleared1995200020052010201520202025
  1. This deviceK984180 The Aptus (Automated) Application of the Rubella Igm Elisa Test SystemZeus Scientific, Inc. · 1999
  2. Descendant · cites it directly · 2 of its ownK092322 Elecsys Rubella Igm ImmunoassayRoche Diagnostics · 2010
  3. Descendant · cites it directly · 2 of its ownK072617 Elecsys Rubella Igg ImmunoassayRoche Diagnostics Corp. · 2008
  4. Descendant · 2 generations on · 1 of its ownK142133 Elecys CMV Igm Immunoassay; Elecys Precicontrol CMV IgmRoche Diagnostics · 2014
  5. Descendant · 2 generations on · 1 of its ownK131605 Elecsys Precicontrol CMV Igg, Elecsys CMV Igg ImmunoassayRoche Diagnostics · 2014
  6. Descendant · 3 generations on · 0 of its ownK220911 Elecsys CMV IgGRoche Diagnostics · 2022

Showing 5 of 6 descendants. See all descendants

Descendants cleared per year

2008: 12010: 12014: 22017: 12022: 1
2008high 2 (2014) · low 0 (2009)2026

Most influential descendants

Showing 5 of 6 · See all
  • K092322Elecsys Rubella Igm ImmunoassayRoche Diagnostics · 2010 · cites it directly2descendants
  • K072617Elecsys Rubella Igg ImmunoassayRoche Diagnostics Corp. · 2008 · cites it directly2descendants
  • K142133Elecys CMV Igm Immunoassay; Elecys Precicontrol CMV IgmRoche Diagnostics · 2014 · 2 generations on1descendant
  • K131605Elecsys Precicontrol CMV Igg, Elecsys CMV Igg ImmunoassayRoche Diagnostics · 2014 · 2 generations on1descendant
  • K220911Elecsys CMV IgGRoche Diagnostics · 2022 · 3 generations on0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)K984180The Aptus (Automated) Application of the Rubella Igm Elisa Test SystemZeus Scientific, Inc.1999—
+1K092322Elecsys Rubella Igm ImmunoassayRoche Diagnostics2010—
+1K072617Elecsys Rubella Igg ImmunoassayRoche Diagnostics Corp.2008—
+2K142133Elecys CMV Igm Immunoassay; Elecys Precicontrol CMV IgmRoche Diagnostics2014—
+2K131605Elecsys Precicontrol CMV Igg, Elecsys CMV Igg ImmunoassayRoche Diagnostics2014—
+3K220911Elecsys CMV IgGRoche Diagnostics2022—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
200810
201010
201420
201710
202210
FIG. 1 — Lineage of K984180, 1999–2022Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA 510(k) statement (indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LFX? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new LFX device

  1. #1 K250588 Access Rubella IgGscore 10.4 · 1 generation · no Class I recall
  2. #2 Held for the reportin the report
Get a 510(k) Report

What was it cleared against?

FDA’s file for it is a 510(k) statement, which names no predicate.

What descends from it? (6)

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K092322Elecsys Rubella Igm ImmunoassayRoche Diagnostics20102
K072617Elecsys Rubella Igg ImmunoassayRoche Diagnostics Corp.20082

Has anything in its family been recalled? (0 Class I)

Recalls of this device

DateClassRecallRoot causeReason
Feb 24, 2000Not classifiedZ-1065-03OtherThe high positive control/low positive standard ratio recovering too low.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K092322 (Roche Diagnostics, 2010) has gone furthest, with 2 descendants of its own.

How does its category compare?

All LFX devices

LFX Enzyme Linked Immunoabsorbent Assay, Rubella: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · LFX

2in 2025

2007: 12008: 32010: 22011: 12012: 12025: 2
2007high 3 (2008) · low 0 (2009)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LFX

354in 2008

2008: 354 days median
2007high 354 (2008)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · LFX

1in 2021

2007: 22008: 22009: 32010: 22011: 12016: 22021: 1
2007high 3 (2009) · low 0 (2012)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · LFX

12in 2025

2007: 52008: 3672009: 192010: 182011: 892012: 372013: 152014: 132015: 152016: 472017: 102018: 242019: 162020: 212021: 132022: 132023: 72024: 132025: 12
2007high 367 (2008) · low 5 (2007)2025

MAUDE reports naming product code LFX, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—25
200833542367
20090—319
20102—218
20111—189
20121—037
20130—015
20140—013
20150—015
20160—247
20170—010
20180—024
20190—016
20200—021
20210—113
20220—013
20230—07
20240—013
20252—012
20260—0—

What is it indicated for?

The Rubella IgM ELISA test system is and enzyme-linked immunosorbent assay (ELISA) designed for the manual or automated (Aptus), qualitative determination of IgM-class antibody to rubelia virus in human serum. The test is intended to be used to evaluate serologic evidence of primary or active infection with Rubella and is for in vitro diagnostic use.

Indications for use read by OCR from a scanned FDA 510(k) statement, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K984180: The Aptus (Automated) Application of the Rubella Igm Elisa Test System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K984180

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026